roxy_nash said:

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

No disagreement, though the timescale matters more than the mechanism here. Most of what looks like a difference in kind turns out to be a difference in how long somebody waited.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

claudia_zurich said:

The mechanism is more central than most summaries suggest.

Thank you for spelling out the reasoning rather than just the conclusion.

roxy_nash said:

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

I read this differently. The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is unsatisfying.

That is the short version; the long version is somebody else's post.

Adding the numbers, since they settle part of this. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Carry on.